Skip to content
Skip to navigation menu

 

Studies on the exacerbation of pulmonary inflammation by viral infection

Introduction

 

Based on their previous experience and range of models of asthma, Prof. Broadley, Dr Ford and Dr Kidd have been awarded a contract for £63000 from RespiVert Ltd.

RespiVert Ltd. is a small molecule drug discovery company working on the identification of a new generation of inhaled medicines for life-threatening lung diseases including severe asthma, chronic obstructive pulmonary disease (COPD) and cystic fibrosis.


Aims of Project

To study  the exacerbation of pulmonary inflammation by viral infection




Funder

RespiVert Ltd

Project Value

£62,997

Duration

one year

Dr William Ford

Position:Senior Lecturer
Contact silhouette green
Telephone: +44 (0)29 208 74781 Extension: 74781

Prof Kenneth Broadley

Position:Professor
Contact silhouette green
Telephone: +44 (0)29 208 75832

Dr Emma Kidd

Position:Reader & Director of Postgraduate Research Studies (SPPS)
Image of Dr Emma Kidd
Telephone: +44 (0)29 208 75803